APsense

  • Our Services

    We offer best-in-class research and consulting services pertaining to the markets of all geographies. Our experienced team of business analysts and consultants has mastered fundamental and advanced market research in diverse industries.

  • Syndicated Research

    Syndicated research is the most cost-effective market research approach, which gives an analytical outlook of the competitive positioning, product positioning, and size estimation of the market at the micro level. Our off-the-shelf reports offer key market insights that industry stakeholders require to base their business strategy on. Our syndicated research services empower our clients to meet diverse market objectives.

  • Customized Research

    we also deliver customized research services to address specific needs of our clients. With a vast pool of adroit analysts who are proficient in market research, we take pride in tailoring our research services to meet our clients’ definite requirements and aid their business growth.

  • Consulting Services

    Businesses, today, need to adapt themselves to the changes that transpire in the market. Staying abreast of the market trends, therefore, becomes imperative for accomplishing business objectives.

  • Our Vision

    To be the most trusted partner in our clients' success endeavors

Showing posts with label Beta Secretase Inhibitors Pipeline. Show all posts
Showing posts with label Beta Secretase Inhibitors Pipeline. Show all posts

Beta-Secretase (BACE) Inhibitors Pipeline to Witness Huge R&D Investment in the Coming Years

The study analysed that the BetaSecretase inhibitors pipeline comprised 15 drug candidates, in different stages of development.

As per the findings of the research, most of the pipeline drug candidates of BACE inhibitors are being developed to be administered by oral route.







Among BACE inhibitors, AZD3293, a drug candidate of AstraZeneca plc and Eli Lilly and Company, received Fast Track designation by the U.S. Food and Drug Administration (FDA) in August 2016. The FDA’s Fast Track program was designed to expedite the development and review new therapies to treat serious conditions and tackle unmet medical needs.


The research finds that different companies collaborated for the development of BACE inhibitors. Novartis entered in a global collaboration with Amgen to commercialize and develop BACE inhibitor program in September 2015 for Alzheimer's disease.
Some of the key players developing BACE inhibitors are AstraZeneca plc, Eli Lilly & Company, Johnson & Johnson, and others.
BACE Inhibitors Pipeline Analysis
·         By Route of Administration
·         By Phase
·         By Company


Contact:
Mr. Kundan Kumar
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +18887787886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Connect with us: LinkedIn | Twitter | Google + | Facebook
Share:

Popular Posts

Labels

Linkedin Profile

APSense

Business Network

Recent Posts

Research Pages